All enrolled individuals who obtained at the least just one dose of zosuquidar or placebo throughout induction were being monitored for that event of adverse activities (439 individuals, 219 on zosuquidar and 210 on placebo). The commonest adverse gatherings had been associated with the duration of prolonged and significant myelosuppression https://knoxfqair.activablog.com/27679397/a-secret-weapon-for-ly-3000328